Panion Animal Health AB develops a new treatment for dogs with epilepsy, based on CombiGene’s gene therapy vector for human epilepsy.
In spring 2018, a safety study in dogs was started under the lead of Associate Professor David Woldbye, Department of Neuroscience, University of Copenhagen. The animal phase of the study was finalized in August 2018, whereas the laboratory testing and imaging and the pathology examinations were performed during fall and winter. The final report has now been released.
The study tested the health reactions and potential adverse effects of the intracranial